EUCTR2005-000515-95-ES进行中（未招募）不适用
Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women with Osteoporosis: A Histomorphometric StudyEfectos diferenciales de la teriparatida y del ranelato de estroncio en el remodelado y la formación ósea en mujeres posmenopáusicas con osteoporosis: Estudio histomorfométrico - GHCX
illy S.A.0 个研究点目标入组 80 人开始时间: 2005年7月28日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients are eligible to be included in the study only if they meet all of the following criteria:
- •[1]Ambulatory, postmenopausal women aged 45 to 90 years inclusive at the time of entry into the trial, whose last menstrual period or bilateral oophorectomy occurred at least 5 years prior to entry into the trial. Women below the age of 55 years in whom a bilateral oophorectomy cannot clearly be documented must have their postmenopausal status confirmed by a serum FSH level ³30 IU/L and serum estradiol level £20 pg/ml or £73 pmol/L.
- •[2]Free of severe or chronically disabling conditions other than osteoporosis.
- •[3]Able to use a pen-type injection delivery system satisfactorily in the opinion of the investigator and willing to be trained on and use the pen-injector on a daily basis.
- •[4]Without language barrier, cooperative, expected to return for all follow-up procedures, and have given informed consent after being informed of the risks, medications, and procedures to be used in the study.
- •[5]Posterior-anterior lumbar spine (L-1 through L-4) BMD and/or femoral neck BMD and/or total hip BMD measurement at least 2.5 standard deviations (SD) below the average bone mass for young women (T-score equal or below to -2.5 standard deviations).
- •The lumbar spine and hip BMD assessment and the determination of the patient’s eligibility for entry into the screening phase will be made by the individual investigator. Any lumbar vertebra that cannot be analyzed due to artifacts, severe crush fracture, osteophytes, or other abnormalities, should be excluded from the analysis. A minimum of two lumbar vertebrae in the L-1 through L-4 region must be evaluable by DXA if this is the only anatomical site where the BMD cut-off level <-2.5 SD is demonstrated. A DXA assessment performed within three months prior to Visit 1 may be acceptable for patient´s eligibility.
- •[6]Normal or clinically insignificant abnormal laboratory values (as defined by the investigator) including serum calcium, PTH(1?84), alkaline phosphatase.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •[7]History of unresolved skeletal diseases that affect bone metabolism other than postmenopausal osteoporosis including Paget's disease, renal osteodystrophy, osteomalacia, any secondary causes of osteoporosis, hyperparathyroidism (uncorrected), and intestinal malabsorption.
- •[8]In the opinion of the investigator, have any medical or anatomical condition that potentially could put the patient at additional risk of an adverse event due to the biopsy procedure (for example, coagulation abnormality, anticoagulant medication, extreme obesity, etc).
- •[9]Have undergone two previous transiliac bone biopsies (one in each iliac crest). Patients with one previous transiliac bone biopsy are eligible provided that the new sample is obtained from the contralateral iliac crest.
- •[10]History of malignant neoplasms in the 5 years prior to Visit 1, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. Patients with carcinoma in situ of the uterine cervix treated definitively more than 1 year prior to entry into the study may be randomized.
- •[11]Increased baseline risk of osteosarcoma; this includes subjects with Paget’s disease of the bone, previous primary skeletal malignancy, or skeletal exposure to therapeutic irradiation, i.e. prior external beam or implant radiation therapy. As an elevation of serum skeletal alkaline phosphatase activity may indicate the presence of Paget’s disease, an unexplained elevation of this enzyme activity will also be exclusionary.
- •[12]Abnormal thyroid function not corrected by therapy. Normal thyroid function may be documented by a normal TSH during the screening phase or a combination of clinical and biochemical parameters which, in the judgment of the investigator and the Lilly Clinical Research Physician, sufficiently establishes the presence of normal thyroid function.
- •[13]Active liver disease or clinical jaundice.
- •[14]Significantly impaired renal function as defined by either of the following criteria:Serum creatinine that, in the opinion of the investigator, indicates significant renal impairment / Measured or calculated endogenous creatinine clearance <30 mL/min using the Cockcroft?Gault formula for creatinine clearance
- •[15]Women who do not qualify for therapy according to the prescribing information for strontium ranelate, including patients with increased risk or past history of venous thromboembolism, and phenylketonuria.
- •[16]History of excessive consumption of alcohol or abuse of drugs in the 1 year prior to Visit 2 in the opinion of the investigator.
- •[17]Poor medical or psychiatric risk for treatment with an investigational drug in the opinion of the investigator.
- •[18]Current or past treatment with any bisphosphonate, parathyroid hormone or its analogs, androgens or other anabolic steroids or therapeutic doses of fluorides at any time prior to Visit 2.
- •Past treatment (more than 12 months before Visit 2) with a selective estrogen receptor modulator (SERM), nasal or injectable calcitonin, oral, transdermal, or injectable estrogens, progestins, estrogen analogs, estrogen agonists, estrogen antagonists or tibolone is allowed. Previous or current use of fluoridated water or topical dental fluoride treatments are permitted.
- •[19]Treatment with Vitamin D >50,000 IU/week, or with any dose of calcitriol or Vitamin D analogs or agonists in the 6 months prior to Visit 2.
- •[20]Treatment with systemic corticosteroids in the last month prior to Vi
研究者
相似试验
进行中（未招募）
不适用
Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women with Osteoporosis: A Histomorphometric Study - GHCXOsteoporosisEUCTR2005-000515-95-CZEli Lilly and Company Limited68
进行中（未招募）
不适用
Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women with Osteoporosis: A Histomorphometric Study - GHCXOsteoporosisEUCTR2005-000515-95-DEEli Lilly and Company Limited68
进行中（未招募）
1 期
Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Bone Mineral Density in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip FracturePostmenopausal Women and Men with Low Bone Mass and a Recent Pertrochanteric FractureMedDRA version: 17.1Level: PTClassification code 10031282Term: OsteoporosisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2008-002693-35-DKEli Lilly and Company Ltd220
进行中（未招募）
不适用
Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Volumetric Bone Mineral Density in Glucocorticoid-Induced Osteoporosis in Men - NDEUCTR2006-006315-68-ITEli Lilly and Company104
进行中（未招募）
1 期
Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Bone Mineral Density in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip FractureEUCTR2008-002693-35-GBEli Lilly and Company Ltd171